GeneDx Holdings (WGS) EBT Margin (2020 - 2026)
GeneDx Holdings (WGS) posted quarterly EBT Margin of 61.04% for Q1 2026, down 5406.0% year-over-year from 1.15% in Q1 2025, and down 305.13% quarter-over-quarter from 15.07% in Q4 2025.
GeneDx Holdings (WGS) EBT Margin (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has reported EBT Margin for 7 consecutive years, with 61.04% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 5406.0% year-over-year to 61.04%; the TTM figure through Mar 2026 stood at 17.5% (down 587.0% YoY), while the FY2025 annual figure was 4.94%, up 1229.0% from the prior year.
- EBT Margin slipped to 61.04% in Q1 2026 per WGS's latest filing, from 15.07% in the prior quarter.
- Across five years, EBT Margin topped out at 10.29% in Q2 2025 and bottomed at 503.13% in Q4 2022.
- Historically, EBT Margin has averaged 96.09% across 5 years, with a median of 45.6% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 43361 bps — and 2023, when it jumped 45753 bps.
- GeneDx Holdings' EBT Margin stood at 503.13% in 2022, then soared by 91 bps to 45.6% in 2023, then jumped by 112 bps to 5.66% in 2024, then tumbled by 366 bps to 15.07% in 2025, then plunged by 305 bps to 61.04% in 2026.
- Business Quant data shows WGS's EBT Margin at 61.04% in Q1 2026, 15.07% in Q4 2025, and 6.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 16.04% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.21% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.29% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 22.23% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 6.89% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -12.17% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 22.43% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 28.17% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 13.54% |
| 10 | GeneDx Holdings | 2.08 Bn | 1.94 Bn | 78.24 Mn | -15.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.95% |
| Mar 31, 2026 | -61.04% |
| Dec 31, 2025 | -15.07% |
| Sep 30, 2025 | -6.33% |
| Jun 30, 2025 | 10.29% |
| Mar 31, 2025 | -6.98% |
| Dec 31, 2024 | 5.66% |
| Sep 30, 2024 | -10.87% |
| Jun 30, 2024 | -41.64% |
| Mar 31, 2024 | -32.55% |
| Dec 31, 2023 | -45.60% |
| Sep 30, 2023 | -79.65% |
| Jun 30, 2023 | -96.32% |
| Mar 31, 2023 | -141.72% |
| Dec 31, 2022 | -503.13% |
| Sep 30, 2022 | -93.29% |
| Jun 30, 2022 | -372.75% |
| Mar 31, 2022 | -142.56% |
| Dec 31, 2021 | -69.52% |
| Sep 30, 2021 | 75.80% |